Omalizumab for urticaria treatment in clinical practice: a case series

Aleksandra Lesiak; Igor Bednarski; Anna Maćkowska; Zuzanna Łukasik; Anna Woźniacka; Irmina Olejniczak-Staruch; Joanna Narbutt

doi:10.5114/ada.2018.77666

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2018
vol. 35

Send email

Copy url:

abstract:

Original paper

Omalizumab for urticaria treatment in clinical practice: a case series

Aleksandra Lesiak

,

Igor A. Bednarski

,

Anna Maćkowska

,

Zuzanna Łukasik

,

Anna Woźniacka

,

Irmina Olejniczak-Staruch

,

Joanna Narbutt

Adv Dermatol Allergol 2018; XXXV (4): 372–374

DOI: https://doi.org/10.5114/ada.2018.77666

Online publish date: 2018/08/21

View full text Get citation

Introduction
Omalizumab (Xolair) originally intended to reduce symptoms of moderate to severe asthma uncontrollable with steroids is the first monoclonal antibody approved for treatment of chronic spontaneous urticaria in 2014.

Aim
To evaluate response and potential side effects to omalizumab treatment in clinical practice.

Material and methods
Eleven patients (6 males and 5 females) were recruited into the study. All participants signed written informed consent before enrollment to the study. At the beginning they were receiving 300 mg of omalizumab in a subcutaneous injection every 4 weeks in an outpatient clinic. Five the clinical response was sufficient, the dose of omalizumab was decreased to 150 mg. We evaluated response to the treatment using the Urticaria Activity Score in the last 7 days and the Urticaria Control Test at certain time points.

Results
Nine out of 11 patients achieved complete syndrome resolution. Five patients achieved clinical remission after the first dose of omalizumab. Mean time to remission was 9.3 weeks. During the study, no side effects were observed.

Conclusions
Omalizumab appears to be a safe drug, which in a quick and effective way inducts remission in patients who have not responded to previous treatment.

keywords:

Omalizumab for urticaria treatment in clinical practice: a case series

Aleksandra Lesiak , Igor A. Bednarski , Anna Maćkowska , Zuzanna Łukasik , Anna Woźniacka , Irmina Olejniczak-Staruch , Joanna Narbutt

urticaria, omalizumab, chronic spontaneous urticaria

Aleksandra Lesiak

,

Igor A. Bednarski

,

Anna Maćkowska

,

Zuzanna Łukasik

,

Anna Woźniacka

,

Irmina Olejniczak-Staruch

,

Joanna Narbutt